Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the ...
Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...
The European Union's executive arm proposed Tuesday to give farmers early access to some €45 billion as it looks to diffuse ...
This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...
A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
The first part of this series focused on the section of Gerrard Street East between Broadview Avenue and the Carlaw-Pape ...
The targets are moving, more diffuse, it’s more complex. Before, the enemy was clear. Now some are wearing suits, some are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback